

Figure 1A

HLA-A2/BMLF1 tetramer

FIGURE 1





Figure 1B

Mutated HLA-A2/BMLF1 tetramer




WO 01/18053

PCV/FR00/02443

1/1

FIGURE 2

HLA-A2/pp65 TETRAMERS




WO 01/18053

PCT/FR00/02443

3/7

FIGURE 3




PCT/FR00/02443

47

**FIGURE 4**



CD3  
marking



**FIGURE 4C**

mutated  
Bmr1/A2  
tetramer  
marking

**Ratio of mutated tetramer AFI/CD3 AFI**

**A2.10: 0,43**


**A4.5: 0,47**

WO 01/16053

PCT/FR00/02443

FIGURE 5

5/7




WO 01/18053

PCT/FR00/02443


Marking before screening

6/7


FIGURE 6



Marking after screening with normal A2/pp65 tetramer



Marking after screening with mutated A2/pp65 tetramer




WO 01/18053

PCT/FR00/02443

7/7

FIGURE 7

Patient 1Patient 2